ORTX News and Press, Orchard Therapeutics plc From 02/05/21

Orchard Therapeutics (ORTX) trades 10.5% high in premarket trade after executing a securities purchase agreement to raise gross proceeds of $150M through the sale of 24.1M shares in a PIPE financing at $6.22/share.Proceeds to be used for supporting its growing commercial capabilitie...

BOSTON and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise gross proceeds of $150 million resulting from the sale of 24,115,755 shares through a private...

Orchard Therapeutics (ORTX) announces the appointment of healthcare and biotech industry veteran Braden Parker as its Chief Commercial Officer.Parker has 20 years of experience in the field and previously held positions at Celgene and PTC Therapeutics. He joined Orchard from PT...

BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of com...

Nine abstracts accepted demonstrating potential of HSC gene therapy to treat multiple neurodegenerative disorders New clinical data from all eight patients treated with OTL-203 for Mucopolysaccharidosis type I (MPS I) Biomarker data from first three patients treated with...

BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and ...

The FDA has granted Orchard Therapeutics' (ORTX) OTL-200 its Regenerative Medicine Advanced Therapy ((RMAT)) designation for the treatment of early-onset metachromatic leukodystrophy ((MLD)), a rare hereditary disorder characterised by accumulation of fats called sulfatides.The agen...

BOSTON and LONDON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OTL-200, an investigational ex ...

Citing the impact of the COVID-19 pandemic on certain development activities, Orchard Therapeutics ([[ORTX]] -3.9%) now expects to file US marketing application for OTL-103 in Wiskott-Aldrich Syndrome ((WAS)), in 2022.The company said that delayed activities is impacting the ti...

Preparations on Track for First Half 2021 Commercial Launch of Libmeldy™ (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU Filing Strategy for OTL-200 Biologics License Application (BLA) in MLD in the U.S. to be Communicated by Mid-202...